Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver fibrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    382 result(s) found for: Liver fibrosis. Displaying page 7 of 20.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2010-021515-17 Sponsor Protocol Number: N/A Start Date*: 2010-09-30
    Sponsor Name:Imperial College London
    Full Title: RiFL: Rifaxamin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?
    Medical condition: Non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053219 non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002325-37 Sponsor Protocol Number: H80-MC-O008 Start Date*: 2008-07-08
    Sponsor Name:Department of Medicine I, University Hospital St. Josef-Hospital, Ruhr University Bochum
    Full Title: Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group t...
    Medical condition: Non alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005245-32 Sponsor Protocol Number: CF102-212LD Start Date*: 2023-05-09
    Sponsor Name:CanFite BioPharma Ltd.
    Full Title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
    Medical condition: Non-Alcoholic Steatohepatitis (NASH) and F1-3 fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000837-39 Sponsor Protocol Number: CCD01 Start Date*: 2007-08-15
    Sponsor Name:Cytonet GmbH & Co. KG
    Full Title: Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure n...
    Medical condition: Acute Liver Failure Subgroups of patients with indications falling under ICD classification codes:K70.4, K71, K72, K75, K76, K77
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049844 Acute liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010806-12 Sponsor Protocol Number: COLO400A2430 Start Date*: 2009-07-22
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ...
    Medical condition: pacientes con trasplante hepático con infección recurrente por Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10024716 Liver transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) IT (Completed) HU (Completed) FR (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003547-36 Sponsor Protocol Number: NRL972-09/2008- (CHBC) Start Date*: 2009-02-12
    Sponsor Name:Norgine Ltd
    Full Title: An open study to investigate the effects of chronic hepatitis B or C on the pharmacokinetics of cholyl-lysyl-fluorescein (NRL972) before, during and after standard treatment
    Medical condition: In-vivo diagnostic marker for liver dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009213 Cirrhosis of liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000311-98 Sponsor Protocol Number: P2005V3 Start Date*: 2005-11-09
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial (pilot study) of the use of macerated garlic oil in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa
    Medical condition: Chronic pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004645-36 Sponsor Protocol Number: TMP-2501-2019-2 Start Date*: 2021-05-31
    Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)
    Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER)
    Medical condition: Drug-induced elevated liver enzymes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024668 Liver damage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003313-35 Sponsor Protocol Number: DCR-A1AT-201 Start Date*: 2022-01-18
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 ...
    Medical condition: PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) NL (Ongoing) PT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FR (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004141-24 Sponsor Protocol Number: 228763 Start Date*: 2018-01-26
    Sponsor Name:Brighton and Sussex University Hospitals NHS Trus
    Full Title: A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised backgro...
    Medical condition: Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    20.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003575-21 Sponsor Protocol Number: Start Date*: 2017-07-25
    Sponsor Name:MRC Clinical Trials Unit at UCL
    Full Title: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy.
    Medical condition: Hepatic steatosis in adults with chronic HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002162-38 Sponsor Protocol Number: PSS2018/REALIST-GUERCI/AS Start Date*: 2018-09-14
    Sponsor Name:CHRU de Nancy
    Full Title: Researching an Effect of GLP-1 Agonist on liver STeatosis (REALIST). A Multicentre controlled and randomized Study assessing the effect of Dulaglutide (TRULICITY®) add-on to dietary reinforcement v...
    Medical condition: Patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis (NASH).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003119-22 Sponsor Protocol Number: EYP001-202 Start Date*: 2019-05-20
    Sponsor Name:ENYO Pharma SA
    Full Title: A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis with likely stage F2 to F3 fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-001260-36 Sponsor Protocol Number: MEN-TOS Start Date*: 2008-03-04
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Terapia PEG-Interferone alfa 2B+Ribavirina versus terapia PEG-Interferone alfa 2B + Ribavirina+ Terapia ormonale sostitutiva (TOS) nella prevenzione della progressione della fibrosi epatica nell’ep...
    Medical condition: Women in post-menopause with Chronic HCV positive hepatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000068-86 Sponsor Protocol Number: AROAAT2002 Start Date*: 2019-07-01
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002833-31 Sponsor Protocol Number: CLMB763X2201 Start Date*: 2017-02-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic stea...
    Medical condition: non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001445-12 Sponsor Protocol Number: GS-US-454-6075 Start Date*: 2022-02-25
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and...
    Medical condition: Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000413-31 Sponsor Protocol Number: 15871A Start Date*: 2014-07-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Exploratory, interventional, open-label, fixed-dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment
    Medical condition: Alcohol dependence and liver impairment related to alcohol consumption
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004873 10001594 Alcohol dependence syndrome LLT
    17.1 100000004871 10021520 Impaired liver function LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003585-27 Sponsor Protocol Number: GNS561CLIQ0211 Start Date*: 2018-01-11
    Sponsor Name:GENOSCIENCE PHARMA
    Full Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer
    Medical condition: Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Pancreatic adenocarcinoma with liver metastasis Colorectal cancer with liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 100000004864 10077738 Hepatocellular carcinoma metastatic LLT
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003367-19 Sponsor Protocol Number: NUC-5/PSC Start Date*: 2017-09-28
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
    Medical condition: Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) LT (Completed) FI (Trial now transitioned) CZ (Prematurely Ended) BE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) SE (Completed) NO (Trial now transitioned) PL (Trial now transitioned) IE (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 11:54:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA